EIQ.AX is trading 31.5% up today at A$1.63 after securing a strategic investment and distribution deal with Pro Medicus. - Pro Medicus will make an initial A$10 million investment in Echo IQ and partner to sell its AI-powered cardiology products in the U.S.. - The deal significantly strengthens Echo IQ's U.S. commercialization strategy and follows existing expectations of imminent U.S. FDA 510(k) clearance for its EchoSolv-HF heart failure AI tool, validated by Mayo Clinic data. - This strategic partnership provides a concrete, company-specific catalyst for the significant price movement, alongside ongoing regulatory optimism.